about
Breast cancer in the personal genomics eraTaxane Combination Chemotherapy in Breast Cancer: Experience from a Tertiary Cancer Centre in India.Feasibility and Efficacy of Eribulin Mesilate in Korean Patients with Metastatic Breast Cancer: Korean Multi-center Phase IV Clinical Study Results.The Impact of CYP2D6 Genotyping on Tamoxifen TreatmentGlobal cancer research initiativeGenetic factors affecting drug disposition in Asian cancer patients.Adjuvant hormonal therapy in premenopausal women with operable breast cancer: not-so-peripheral perspectivesRelationship between genotypes Sult1a2 and Cyp2d6 and tamoxifen metabolism in breast cancer patientsBreast cancer: a neglected disease for the majority of affected women worldwideLapatinib-induced hepatitis: a case report.Advances in breast cancer: pathways to personalized medicinePharmacogenetics in breast cancer: steps toward personalized medicine in breast cancer managementGenetically engineered mouse models in cancer researchGenetic susceptibility loci for breast cancer by estrogen receptor statusPolymorphism of CYP3A4 and ABCB1 genes increase the risk of neuropathy in breast cancer patients treated with paclitaxel and docetaxel.CYP19 genetic polymorphism haplotype AASA is associated with a poor prognosis in premenopausal women with lymph node-negative, hormone receptor-positive breast cancer.Anastrozole Use in Early Stage Breast Cancer of Post-Menopausal Women.Multidrug-resistant breast cancer: current perspectives.Adjuvant tamoxifen influences the lipid profile in breast cancer patientsPharmacogenetics in breast cancer: focus on hormone therapy, taxanes, trastuzumab and bevacizumab.Efficacy and pharmacogenomic biomarkers in breast cancer.Phase I clinical trial of vinorelbine in tumor-bearing cats.SNPs and taxane toxicity in breast cancer patients.Lack of any association between functionally significant CYP2D6 polymorphisms and clinical outcomes in early breast cancer patients receiving adjuvant tamoxifen treatment
P2860
Q24602679-02AAFCAA-9D23-454D-9334-449F2876DBCBQ33441582-F34A2654-B25D-46EB-9550-131CC68F002BQ33584160-1B49467B-CF31-47EF-8664-C4419873968CQ33664433-161CC1FF-9772-42BA-9349-4001F4182F4FQ34417827-28C924D6-709E-4A16-8FC2-9DB34773F7EAQ34501025-FBA09419-2034-4B61-9217-73E43B8FC146Q34774649-D96DBA67-6BC6-4363-A961-E653E6A9C426Q34906432-149A8859-26BD-425B-95B2-3C6BDF976B14Q34949553-B4B99820-CB92-458E-BEEF-2DB39112BA60Q34993721-C3E92025-32DC-4472-9FB3-7FCD87A84C23Q35951346-981A6155-EBF8-4F7A-8E1D-CFA762E194C9Q36441485-4E563E51-D314-4F75-A5A8-45888DBC74BAQ36497718-D82811BD-CCAB-4583-8ED7-8F575BC4E1A0Q37156413-90F6AECB-C62D-4A3D-BA9D-1A46E7656293Q37187663-D79E20D2-F047-494B-AC6D-6C662CF25C28Q37353704-4BB0ECDC-825E-4163-8FD4-B21EC04296A2Q37366511-E0949D37-A114-4D22-8469-FB2016543683Q37593383-4846EAD1-7956-49DA-8F4A-10E712CF7C1FQ37716225-FA71F3AE-E378-45E7-B401-F7C65ACE8454Q37725978-2FEA62FE-9B16-4979-94ED-F483946F13CBQ37997046-682CCFBE-9FB1-4A00-A617-A776B0D4FDEBQ43410960-C5A6D073-494F-4824-8BE4-1400A7C89A86Q46800256-96AD6796-1082-41E9-93D1-0859B999A1AAQ57225860-6754714A-6DAE-47A5-B040-BDEDC4F97C8B
P2860
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on December 2008
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Pharmacogenetics in breast cancer therapy.
@en
Pharmacogenetics in breast cancer therapy.
@nl
type
label
Pharmacogenetics in breast cancer therapy.
@en
Pharmacogenetics in breast cancer therapy.
@nl
prefLabel
Pharmacogenetics in breast cancer therapy.
@en
Pharmacogenetics in breast cancer therapy.
@nl
P2093
P1476
Pharmacogenetics in breast cancer therapy.
@en
P2093
Boon-Cher Goh
Sing-Huang Tan
Soo-Chin Lee
P304
P356
10.1158/1078-0432.CCR-08-0993
P407
P577
2008-12-01T00:00:00Z